Judith Moss
Family Medicine · Clermont, FLNPI 1013942317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $824 and has fallen 92.6% since, to $61 in 2024.
Across 116 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$351
- AbbVie$334
- AstraZeneca$178
- Lilly USA, LLC$145
- Abbott$127
- Pfizer$85
- plus $732 from 19 others
What the payments were for
- Food & beverage$1,953100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $351 |
| AbbVie(2 entities) | 20 | $334 |
| AstraZeneca | 10 | $178 |
| Lilly USA, LLC | 10 | $145 |
| Abbott | 6 | $127 |
| Pfizer | 6 | $85 |
| Amgen(2 entities) | 5 | $84 |
| GSK | 2 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Amarin Pharma, Inc. | 4 | $70 |
| Boehringer Ingelheim | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Novartis | 3 | $58 |
| Bayer | 2 | $53 |
| Merck | 3 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Phadia US Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$1,953 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $11,015 |
| Rosuvastatin Calcium | 15 | $191 |
| Clonazepam | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $62 | $11,01519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Clermont
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.